董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David I. Bruce | 男 | Director | 58 | 未披露 | 未持股 | 2018-05-04 |
| Maria Sainz | 女 | Director | 52 | 未披露 | 未持股 | 2018-05-04 |
| William M. Moore | 男 | Director,Chairman,President and Chief Executive Officer | 69 | 226.47万美元 | 未持股 | 2018-05-04 |
| Sanford Fitch | 男 | Director | 77 | 9.87万美元 | 未持股 | 2018-05-04 |
| Ruediger Naumann Etienne | 男 | Director | 71 | 14.07万美元 | 未持股 | 2018-05-04 |
| Ann D. Rhoads | 女 | Director | 53 | 16.70万美元 | 未持股 | 2018-05-04 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Atabak Mokari | 男 | Chief Financial Officer and Vice President of Corporate Development | 41 | 105.07万美元 | 未持股 | 2018-05-04 |
| William M. Moore | 男 | Director,Chairman,President and Chief Executive Officer | 69 | 226.47万美元 | 未持股 | 2018-05-04 |
董事简历
中英对照 | 中文 | 英文- David I. Bruce
-
DavidI.Bruce，布鲁斯先生自2018年4月起担任公司董事。Bruce先生于2014年8月至2016年5月担任Catheter Robotics，Inc.（一家私人公司，专注于开发和制造远程导管系统）的首席运营官。2011年11月至2014年5月，Bruce先生担任Arstasis，Inc.的总裁，首席执行官兼董事，该公司是一家私人公司，制造和分销用于导管插管过程中动脉闭合的血管闭合设备。Bruce从2009年1月到2009年5月担任Patient Safety Technologies，Inc.（一家公共医疗设备公司）首席执行官和董事。他曾担任EP MedSystems Inc.（一家公共医疗设备公司）的首席执行官兼董事，后于2006年8月至2008年12月出售给圣犹达医疗公司。Bruce先生拥有加州大学伯克利分校（University of California，Berkeley）机械工程学士学位，以及宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
David I. Bruce,Mr. Bruce has served as a director of the Company since April 2018. Mr. Bruce served as the Chief Operating Officer of Catheter Robotics, Inc., a private company focused on developing and manufacturing remote catheter systems from August 2014 to May 2016. From November 2011 to May 2014 Mr. Bruce served as President, Chief Executive Officer and director of Arstasis, Inc., a private company that manufactures and distributes vascular closure devices for arterial closure in catheterization procedures. Mr. Bruce was Chief Executive Officer and Director of Patient Safety Technologies, Inc., a public medical device company from January 2009 to May 2009. He was Chief Executive Officer and Director of EP MedSystems Inc., a public medical device company before selling to St. Jude Medical, Inc. from August 2006 until December 2008. Mr. Bruce holds a B.S. in Mechanical Engineering from the University of California, Berkeley, and an MBA from the Wharton School at the University of Pennsylvania. - DavidI.Bruce，布鲁斯先生自2018年4月起担任公司董事。Bruce先生于2014年8月至2016年5月担任Catheter Robotics，Inc.（一家私人公司，专注于开发和制造远程导管系统）的首席运营官。2011年11月至2014年5月，Bruce先生担任Arstasis，Inc.的总裁，首席执行官兼董事，该公司是一家私人公司，制造和分销用于导管插管过程中动脉闭合的血管闭合设备。Bruce从2009年1月到2009年5月担任Patient Safety Technologies，Inc.（一家公共医疗设备公司）首席执行官和董事。他曾担任EP MedSystems Inc.（一家公共医疗设备公司）的首席执行官兼董事，后于2006年8月至2008年12月出售给圣犹达医疗公司。Bruce先生拥有加州大学伯克利分校（University of California，Berkeley）机械工程学士学位，以及宾夕法尼亚大学沃顿商学院（Wharton School at the University of Pennsylvania）工商管理硕士学位。
- David I. Bruce,Mr. Bruce has served as a director of the Company since April 2018. Mr. Bruce served as the Chief Operating Officer of Catheter Robotics, Inc., a private company focused on developing and manufacturing remote catheter systems from August 2014 to May 2016. From November 2011 to May 2014 Mr. Bruce served as President, Chief Executive Officer and director of Arstasis, Inc., a private company that manufactures and distributes vascular closure devices for arterial closure in catheterization procedures. Mr. Bruce was Chief Executive Officer and Director of Patient Safety Technologies, Inc., a public medical device company from January 2009 to May 2009. He was Chief Executive Officer and Director of EP MedSystems Inc., a public medical device company before selling to St. Jude Medical, Inc. from August 2006 until December 2008. Mr. Bruce holds a B.S. in Mechanical Engineering from the University of California, Berkeley, and an MBA from the Wharton School at the University of Pennsylvania.
- Maria Sainz
-
Maria Sainz，Sainz女士自2018年4月起担任公司董事。Sainz女士于2012年5月至2017年7月担任Cardiokinetix Inc.（一家开发经导管植入物的私人公司）的总裁，首席执行官兼董事。Sainz女士于2011年10月至2012年5月被史赛克公司收购，担任神经血管医疗技术公司Concentric Medical，Inc.的总裁兼首席执行官。Sainz女士曾担任Guidant Corporation/Boston Scientific心脏外科部门的总裁，在担任该职位之前，曾担任多个职责递增的销售与市场营销管理职位。Sainz女士目前在Orthofix International NV，Halyard Health，Inc.和MRI Interventions的董事会任职。Sainz女士拥有西班牙马德里the University Complutense的语言硕士学位和美国国际管理研究生院的国际管理硕士学位。
Maria Sainz, Ms. Sainz has served as a director of the Company since April 2018. Ms. Sainz served as the President, Chief Executive Officer, and Director of CardioKinetix Inc., a private company that developed transcatheter implants from May 2012 to July 2017. Ms. Sainz was the President and Chief Executive Officer of Concentric Medical, Inc., a neurovascular medical technology company, through its acquisition by Stryker Corporation in October 2011 until May 2012. Ms. Sainz served as the President of the Cardiac Surgery division of Guidant Corporation/Boston Scientific and prior to that position in several sales and marketing management positions of increasing responsibility. Ms. Sainz currently serves on the board of directors of Orthofix International NV, Halyard Health, Inc. and MRI Interventions. Ms. Sainz holds a M.A. in Languages from the University Complutense in Madrid, Spain and a Master's Degree in International Management from the American Graduate School of International Management. - Maria Sainz，Sainz女士自2018年4月起担任公司董事。Sainz女士于2012年5月至2017年7月担任Cardiokinetix Inc.（一家开发经导管植入物的私人公司）的总裁，首席执行官兼董事。Sainz女士于2011年10月至2012年5月被史赛克公司收购，担任神经血管医疗技术公司Concentric Medical，Inc.的总裁兼首席执行官。Sainz女士曾担任Guidant Corporation/Boston Scientific心脏外科部门的总裁，在担任该职位之前，曾担任多个职责递增的销售与市场营销管理职位。Sainz女士目前在Orthofix International NV，Halyard Health，Inc.和MRI Interventions的董事会任职。Sainz女士拥有西班牙马德里the University Complutense的语言硕士学位和美国国际管理研究生院的国际管理硕士学位。
- Maria Sainz, Ms. Sainz has served as a director of the Company since April 2018. Ms. Sainz served as the President, Chief Executive Officer, and Director of CardioKinetix Inc., a private company that developed transcatheter implants from May 2012 to July 2017. Ms. Sainz was the President and Chief Executive Officer of Concentric Medical, Inc., a neurovascular medical technology company, through its acquisition by Stryker Corporation in October 2011 until May 2012. Ms. Sainz served as the President of the Cardiac Surgery division of Guidant Corporation/Boston Scientific and prior to that position in several sales and marketing management positions of increasing responsibility. Ms. Sainz currently serves on the board of directors of Orthofix International NV, Halyard Health, Inc. and MRI Interventions. Ms. Sainz holds a M.A. in Languages from the University Complutense in Madrid, Spain and a Master's Degree in International Management from the American Graduate School of International Management.
- William M. Moore
-
William M. Moore，担任公司董事会主席，并担任公司总裁兼首席执行官。自2007年9月起担任公司董事，自2010年9月起担任公司董事会主席，自2012年8月起担任公司总裁兼首席执行官。Moore先生于2007年9月至2010年7月担任公司薪酬委员会成员，并于2009年2月至2012年10月担任公司提名和治理委员会主席。摩尔先生目前还担任Natus Medical Incorporated的董事会成员，Natus Medical Incorporated是他于1990年与他人共同创立的一家上市公司，并担任Natus Medical Incorporated的首席执行官至1993年。Natus Medical Incorporated是一家医疗保健产品提供商，用于听力障碍、神经功能障碍、癫痫、睡眠障碍以及某些新生儿状况等常见医疗疾病的筛查、检测、治疗、监测和跟踪。Moore在2004年2月至2008年6月期间担任私募股权公司BlueLine Partners的顾问。从2008年2月到2010年6月，Moore先生在Urologix, Inc.的董事会任职，Urologix, Inc.是一家上市公司，开发、制造和销售用于治疗泌尿系统疾病的微创医疗产品。
William M. Moore,serves as the Chairman of the Company's Board of Directors and as the President and Chief Executive Officer of the Company. He has served as a director of the Company since September 2007 as Chairman of the Company's Board of Directors since September 2010 and as the President and Chief Executive Officer of the Company since August 2012. Mr. Moore served as a member of the Company's Compensation Committee from September 2007 to July 2010 and as the Chairman of the Company's Nominating and Governance Committee from February 2009 to October 2012.Mr. Moore also currently serves on the board of directors of Natus Medical Incorporated, a public company he co-founded in 1990 and for which he served as CEO until 1993. Natus Medical Incorporated is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and certain newborn conditions. Mr. Moore served as a consultant to BlueLine Partners, a private equity firm, from February 2004 until June 2008. From February 2008 to June 2010 Mr. Moore served on the board of directors of Urologix, Inc., a public company that develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. - William M. Moore，担任公司董事会主席，并担任公司总裁兼首席执行官。自2007年9月起担任公司董事，自2010年9月起担任公司董事会主席，自2012年8月起担任公司总裁兼首席执行官。Moore先生于2007年9月至2010年7月担任公司薪酬委员会成员，并于2009年2月至2012年10月担任公司提名和治理委员会主席。摩尔先生目前还担任Natus Medical Incorporated的董事会成员，Natus Medical Incorporated是他于1990年与他人共同创立的一家上市公司，并担任Natus Medical Incorporated的首席执行官至1993年。Natus Medical Incorporated是一家医疗保健产品提供商，用于听力障碍、神经功能障碍、癫痫、睡眠障碍以及某些新生儿状况等常见医疗疾病的筛查、检测、治疗、监测和跟踪。Moore在2004年2月至2008年6月期间担任私募股权公司BlueLine Partners的顾问。从2008年2月到2010年6月，Moore先生在Urologix, Inc.的董事会任职，Urologix, Inc.是一家上市公司，开发、制造和销售用于治疗泌尿系统疾病的微创医疗产品。
- William M. Moore,serves as the Chairman of the Company's Board of Directors and as the President and Chief Executive Officer of the Company. He has served as a director of the Company since September 2007 as Chairman of the Company's Board of Directors since September 2010 and as the President and Chief Executive Officer of the Company since August 2012. Mr. Moore served as a member of the Company's Compensation Committee from September 2007 to July 2010 and as the Chairman of the Company's Nominating and Governance Committee from February 2009 to October 2012.Mr. Moore also currently serves on the board of directors of Natus Medical Incorporated, a public company he co-founded in 1990 and for which he served as CEO until 1993. Natus Medical Incorporated is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and certain newborn conditions. Mr. Moore served as a consultant to BlueLine Partners, a private equity firm, from February 2004 until June 2008. From February 2008 to June 2010 Mr. Moore served on the board of directors of Urologix, Inc., a public company that develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders.
- Sanford Fitch
-
Sanford Fitch，他担任我们的董事（2006年11月以来）。他曾一直担任Iridex公司（一家上市公司，设计、研发、生产和销售医疗激光系统）的董事、审计委员会主席兼报酬委员会成员（2004年以来）。他曾担任FoxHollow Technologies公司（一家上市公司设计、开发、生产和销售医疗设备）的董事兼审计委员会主席（从2004年6月到2007年10月）。他也曾担任Conceptus公司（公共医疗设备公司）的董事兼审计委员会主席（从1994年12月到2004年4月）。他曾担任Conceptus公司的首席财务官兼高级运营副总裁（从1994年12月到1998年10月）。他也曾担任一些初创科技公司的首席财务官（1998年至2002年）。从1990年12月到1994年1月，他担任SanDisk公司（闪存设备的制造商）的首席财务官。从1983年到1989年，他曾担任Komag公司（磁盘驱动器行业媒体的刚性薄膜媒体的制造商）的首席财务官。他获得斯坦福大学（Stanford University）的化学学士学位和工商管理硕士学位。我们的提名、合规和公司治理委员会发现，他的金融背景对董事会是极有帮助的，并适合他担任我们的审计委员会主席。
Sanford Fitch,Mr. Fitch has served as a director of the Company since 2004. Mr. Fitch has served as a director and Audit Committee Chairman of Masimo Corp, a public company that designs, develops, manufactures and sells medical devices, since November 2006. Mr. Fitch served as a director and Audit Committee Chairman of Foxhollow Technologies, Inc., a public company that designed, developed, manufactured and sold medical devices, from June 2004 until October 2007. He also served as a director and Audit Committee Chairman of Conceptus Inc., a public medical device company, from December 1994 until April 2004. Mr. Fitch was Chief Financial Officer and Senior Vice President of Operations of Conceptus from December 1994 through October 1998 and took the company public in 1996. Mr. Fitch also served as Chief Financial Officer of several start-uptechnology companies from 1998 until 2002. From December 1990 to January 1994 Mr. Fitch served as Chief Financial Officer of SanDisk Corp., a manufacturer of flash memory devices. From 1983 through 1989 Mr. Fitch was the Chief Financial Officer of Komag Inc., a manufacturer of rigid thin film media for the disk drive industry, and took the company public in 1987. Mr. Fitch holds a B.S. in Chemistry and an M.B.A. from Stanford University. - Sanford Fitch，他担任我们的董事（2006年11月以来）。他曾一直担任Iridex公司（一家上市公司，设计、研发、生产和销售医疗激光系统）的董事、审计委员会主席兼报酬委员会成员（2004年以来）。他曾担任FoxHollow Technologies公司（一家上市公司设计、开发、生产和销售医疗设备）的董事兼审计委员会主席（从2004年6月到2007年10月）。他也曾担任Conceptus公司（公共医疗设备公司）的董事兼审计委员会主席（从1994年12月到2004年4月）。他曾担任Conceptus公司的首席财务官兼高级运营副总裁（从1994年12月到1998年10月）。他也曾担任一些初创科技公司的首席财务官（1998年至2002年）。从1990年12月到1994年1月，他担任SanDisk公司（闪存设备的制造商）的首席财务官。从1983年到1989年，他曾担任Komag公司（磁盘驱动器行业媒体的刚性薄膜媒体的制造商）的首席财务官。他获得斯坦福大学（Stanford University）的化学学士学位和工商管理硕士学位。我们的提名、合规和公司治理委员会发现，他的金融背景对董事会是极有帮助的，并适合他担任我们的审计委员会主席。
- Sanford Fitch,Mr. Fitch has served as a director of the Company since 2004. Mr. Fitch has served as a director and Audit Committee Chairman of Masimo Corp, a public company that designs, develops, manufactures and sells medical devices, since November 2006. Mr. Fitch served as a director and Audit Committee Chairman of Foxhollow Technologies, Inc., a public company that designed, developed, manufactured and sold medical devices, from June 2004 until October 2007. He also served as a director and Audit Committee Chairman of Conceptus Inc., a public medical device company, from December 1994 until April 2004. Mr. Fitch was Chief Financial Officer and Senior Vice President of Operations of Conceptus from December 1994 through October 1998 and took the company public in 1996. Mr. Fitch also served as Chief Financial Officer of several start-uptechnology companies from 1998 until 2002. From December 1990 to January 1994 Mr. Fitch served as Chief Financial Officer of SanDisk Corp., a manufacturer of flash memory devices. From 1983 through 1989 Mr. Fitch was the Chief Financial Officer of Komag Inc., a manufacturer of rigid thin film media for the disk drive industry, and took the company public in 1987. Mr. Fitch holds a B.S. in Chemistry and an M.B.A. from Stanford University.
- Ruediger Naumann Etienne
-
Ruediger Naumann Etienne自2009年12月起担任公司董事。自1989年以来一直担任Intertec公司集团（投资公司，专门从事医疗设备领域）的所有者和董事总经理。自2006年直到2010年公司被出售给印度的光电技术公司，一直担任心脏科学公司的主席。从2000年至2005年，出任董事长。2000年到2003年，担任昆顿心内科系统（心脏科学的前身公司之一）的首席执行官。从1993年直到1999年，担任OEC医疗系统（荧光透视成像系统制造商）的董事长。自1987年至1990年，担任Diasonics（诊断成像设备的制造商）的总裁兼首席营运官。自2003年以来担任瓦里安医疗系统公司（公共医疗器械公司）的董事会成员。自2008年10月担任Encision公司（公共医疗器械公司）的董事。从2005年9月至2010年12月担任心脏科学公司（公共医疗器械公司）的董事。从2003年10月至2009年12月，担任Bio-Rad实验室公司（一家公众的生命科学公司）的董事。他在密歇根大学获得国际金融博士学位。他在乔治亚技术学院获得工业管理硕士学位，在德国柏林工业大学获得工商管理本科学位。
Ruediger Naumann Etienne,Owner and Managing Director, Intertec Group, an investment company specializing in the medical technology field 1989 - present.Positions at Iridex Corporation.Lead Independent Director (2017 - 2019).Member of the Board of Directors (2009 - 2019).Prior Public Company Board Memberships in Past Five Years: Encision Inc.; Iridex Corporation; and Varian Medical Systems, Inc. - Ruediger Naumann Etienne自2009年12月起担任公司董事。自1989年以来一直担任Intertec公司集团（投资公司，专门从事医疗设备领域）的所有者和董事总经理。自2006年直到2010年公司被出售给印度的光电技术公司，一直担任心脏科学公司的主席。从2000年至2005年，出任董事长。2000年到2003年，担任昆顿心内科系统（心脏科学的前身公司之一）的首席执行官。从1993年直到1999年，担任OEC医疗系统（荧光透视成像系统制造商）的董事长。自1987年至1990年，担任Diasonics（诊断成像设备的制造商）的总裁兼首席营运官。自2003年以来担任瓦里安医疗系统公司（公共医疗器械公司）的董事会成员。自2008年10月担任Encision公司（公共医疗器械公司）的董事。从2005年9月至2010年12月担任心脏科学公司（公共医疗器械公司）的董事。从2003年10月至2009年12月，担任Bio-Rad实验室公司（一家公众的生命科学公司）的董事。他在密歇根大学获得国际金融博士学位。他在乔治亚技术学院获得工业管理硕士学位，在德国柏林工业大学获得工商管理本科学位。
- Ruediger Naumann Etienne,Owner and Managing Director, Intertec Group, an investment company specializing in the medical technology field 1989 - present.Positions at Iridex Corporation.Lead Independent Director (2017 - 2019).Member of the Board of Directors (2009 - 2019).Prior Public Company Board Memberships in Past Five Years: Encision Inc.; Iridex Corporation; and Varian Medical Systems, Inc.
- Ann D. Rhoads
-
Ann D. Rhoads， 自2010年3月起担任执行副总裁、首席财务官和风险官、以及秘书的职位。2000年到2009年12月担任Premier, Inc.（一家医疗保健服务公司）首席财务官，负责金融管理、战略规划、业务开发、信息技术和道德与合规的所有事项。1998年8月到2000年担任Premier战略活动副总裁，负责监管战略投资，包括风险资本基金以及协助Premier的运营部门提供长期战略规划。加入Premier之前，她在Sprout Group（Donaldson, Lufkin & Jenrette的风险资本附属公司，现在是Credit Suisse First Boston, Bain & Company 和 Merrill Lynch Capital Partners的一部份。 Merrill Lynch Capital Partners现名为Stonington Partners） 担任多个职位。她现在是 Globus Medical Inc.和 Evoke Pharma, Inc.董事。她持有Arkansas大学理学学士学位和哈佛商学院（the Harvard Business School。）工商管理硕士学位。
Ann D. Rhoads,served as Chief Financial Officer of Forty Seven, Inc., a formerly publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was the Executive Vice President and Chief Financial Officer of Zogenix, Inc., a formerly publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was the Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Business School. - Ann D. Rhoads， 自2010年3月起担任执行副总裁、首席财务官和风险官、以及秘书的职位。2000年到2009年12月担任Premier, Inc.（一家医疗保健服务公司）首席财务官，负责金融管理、战略规划、业务开发、信息技术和道德与合规的所有事项。1998年8月到2000年担任Premier战略活动副总裁，负责监管战略投资，包括风险资本基金以及协助Premier的运营部门提供长期战略规划。加入Premier之前，她在Sprout Group（Donaldson, Lufkin & Jenrette的风险资本附属公司，现在是Credit Suisse First Boston, Bain & Company 和 Merrill Lynch Capital Partners的一部份。 Merrill Lynch Capital Partners现名为Stonington Partners） 担任多个职位。她现在是 Globus Medical Inc.和 Evoke Pharma, Inc.董事。她持有Arkansas大学理学学士学位和哈佛商学院（the Harvard Business School。）工商管理硕士学位。
- Ann D. Rhoads,served as Chief Financial Officer of Forty Seven, Inc., a formerly publicly-traded biotechnology company, from March 2018 to June 2020. Previously, Ms. Rhoads was the Executive Vice President and Chief Financial Officer of Zogenix, Inc., a formerly publicly-traded pharmaceutical company, from 2010 to January 2017. From 2000 to the end of 2009, Ms. Rhoads served as the Chief Financial Officer of Premier, Inc., a healthcare supply management company. From 1998 to 2000, she was the Vice President, Strategic Initiatives at Premier, Inc., and from 1993 to 1998, she was an investment professional with The Sprout Group, an institutional venture capital firm. Ms. Rhoads holds a B.S. in Finance from the University of Arkansas and an M.B.A. from Harvard Business School.
高管简历
中英对照 | 中文 | 英文- Atabak Mokari
Atabak Mokari，Mokari先生于2016年7月成为我们公司发展的首席财务官兼Vice President。加入公司之前，Mokari从2013年9月到2016年7月担任Wells Fargo Securities高级投资银行家，从2009年9月到2013年7月担任UBS高级投资银行家，从2005年7月到2009年2月担任Credit Suisse高级投资银行家。Mokari先生还在Olympus Partners，and Bowles Hollowell Conner担任职位。Mokari先生在达特茅斯塔克商学院（Tuck School of Business at Dartmouth）获得工商管理硕士学位，在杜克大学（Duke University）获得化学和生物学学士学位。
Atabak Mokari, Mr. Mokari became our Chief Financial Officer and Vice President of Corporate Development in July 2016. Prior to joining the Company, Mr. Mokari was a senior investment banker at Wells Fargo Securities from September 2013 to July 2016 at UBS from September 2009 to July 2013 and at Credit Suisse from July 2005 to February 2009. Mr. Mokari also held positions at Olympus Partners, and Bowles Hollowell Conner. Mr. Mokari earned his MBA from The Tuck School of Business at Dartmouth and BS in Chemistry and Biology from Duke University.- Atabak Mokari，Mokari先生于2016年7月成为我们公司发展的首席财务官兼Vice President。加入公司之前，Mokari从2013年9月到2016年7月担任Wells Fargo Securities高级投资银行家，从2009年9月到2013年7月担任UBS高级投资银行家，从2005年7月到2009年2月担任Credit Suisse高级投资银行家。Mokari先生还在Olympus Partners，and Bowles Hollowell Conner担任职位。Mokari先生在达特茅斯塔克商学院（Tuck School of Business at Dartmouth）获得工商管理硕士学位，在杜克大学（Duke University）获得化学和生物学学士学位。
- Atabak Mokari, Mr. Mokari became our Chief Financial Officer and Vice President of Corporate Development in July 2016. Prior to joining the Company, Mr. Mokari was a senior investment banker at Wells Fargo Securities from September 2013 to July 2016 at UBS from September 2009 to July 2013 and at Credit Suisse from July 2005 to February 2009. Mr. Mokari also held positions at Olympus Partners, and Bowles Hollowell Conner. Mr. Mokari earned his MBA from The Tuck School of Business at Dartmouth and BS in Chemistry and Biology from Duke University.
- William M. Moore
William M. Moore，担任公司董事会主席，并担任公司总裁兼首席执行官。自2007年9月起担任公司董事，自2010年9月起担任公司董事会主席，自2012年8月起担任公司总裁兼首席执行官。Moore先生于2007年9月至2010年7月担任公司薪酬委员会成员，并于2009年2月至2012年10月担任公司提名和治理委员会主席。摩尔先生目前还担任Natus Medical Incorporated的董事会成员，Natus Medical Incorporated是他于1990年与他人共同创立的一家上市公司，并担任Natus Medical Incorporated的首席执行官至1993年。Natus Medical Incorporated是一家医疗保健产品提供商，用于听力障碍、神经功能障碍、癫痫、睡眠障碍以及某些新生儿状况等常见医疗疾病的筛查、检测、治疗、监测和跟踪。Moore在2004年2月至2008年6月期间担任私募股权公司BlueLine Partners的顾问。从2008年2月到2010年6月，Moore先生在Urologix, Inc.的董事会任职，Urologix, Inc.是一家上市公司，开发、制造和销售用于治疗泌尿系统疾病的微创医疗产品。
William M. Moore,serves as the Chairman of the Company's Board of Directors and as the President and Chief Executive Officer of the Company. He has served as a director of the Company since September 2007 as Chairman of the Company's Board of Directors since September 2010 and as the President and Chief Executive Officer of the Company since August 2012. Mr. Moore served as a member of the Company's Compensation Committee from September 2007 to July 2010 and as the Chairman of the Company's Nominating and Governance Committee from February 2009 to October 2012.Mr. Moore also currently serves on the board of directors of Natus Medical Incorporated, a public company he co-founded in 1990 and for which he served as CEO until 1993. Natus Medical Incorporated is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and certain newborn conditions. Mr. Moore served as a consultant to BlueLine Partners, a private equity firm, from February 2004 until June 2008. From February 2008 to June 2010 Mr. Moore served on the board of directors of Urologix, Inc., a public company that develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders.- William M. Moore，担任公司董事会主席，并担任公司总裁兼首席执行官。自2007年9月起担任公司董事，自2010年9月起担任公司董事会主席，自2012年8月起担任公司总裁兼首席执行官。Moore先生于2007年9月至2010年7月担任公司薪酬委员会成员，并于2009年2月至2012年10月担任公司提名和治理委员会主席。摩尔先生目前还担任Natus Medical Incorporated的董事会成员，Natus Medical Incorporated是他于1990年与他人共同创立的一家上市公司，并担任Natus Medical Incorporated的首席执行官至1993年。Natus Medical Incorporated是一家医疗保健产品提供商，用于听力障碍、神经功能障碍、癫痫、睡眠障碍以及某些新生儿状况等常见医疗疾病的筛查、检测、治疗、监测和跟踪。Moore在2004年2月至2008年6月期间担任私募股权公司BlueLine Partners的顾问。从2008年2月到2010年6月，Moore先生在Urologix, Inc.的董事会任职，Urologix, Inc.是一家上市公司，开发、制造和销售用于治疗泌尿系统疾病的微创医疗产品。
- William M. Moore,serves as the Chairman of the Company's Board of Directors and as the President and Chief Executive Officer of the Company. He has served as a director of the Company since September 2007 as Chairman of the Company's Board of Directors since September 2010 and as the President and Chief Executive Officer of the Company since August 2012. Mr. Moore served as a member of the Company's Compensation Committee from September 2007 to July 2010 and as the Chairman of the Company's Nominating and Governance Committee from February 2009 to October 2012.Mr. Moore also currently serves on the board of directors of Natus Medical Incorporated, a public company he co-founded in 1990 and for which he served as CEO until 1993. Natus Medical Incorporated is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and certain newborn conditions. Mr. Moore served as a consultant to BlueLine Partners, a private equity firm, from February 2004 until June 2008. From February 2008 to June 2010 Mr. Moore served on the board of directors of Urologix, Inc., a public company that develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders.